AusperBio Secures Over RMB 1.8 Billion in Six Funding Rounds Within Three Years, Files for IPO

• Accelerate the advancement of core product antisense oligonucleotides（ASO）Innovative Drug AHB-137Used to implementClinical Cure of Chronic Hepatitis BTheClinical trial progress, covering Phase III clinical trials conducted in mainland China, Phase II clinical trials for combination therapy and treatment-naïve patients, as well as concurrently advancing overseas Phase II clinical trials;
• Advance the commercialization and industrialization construction of AHB-137 to ensure its smooth market entry and global availability in the future.Hepatitis BLay the foundation for patients;
• Continuously expand the company's innovative pipeline research and development, strengthen the construction of professional teams at home and abroad, and accumulate core technologies and talent strength for the long-term development of the enterprise.

AusperBio was founded in August 2019, dedicated to the research and development of First-in-class and Best-in-class.Self-innovated Targeted Delivery Small Nucleic Acid Drugs，Core Focus: Chronic Hepatitis B（HBV）Functional cure and highly efficient targeted treatment for liver diseases, while actively expanding into new target areas beyond the liver.The reason for focusing on this track is toFully leverage the strengths of core team members in antiviral drug development。

Cheng Guofeng, as the founder and CEO, is the formerGileadSenior Director of Antiviral New Drug Development, Breakthrough Hepatitis C Curative Innovative Drug Approved for Marketing by the FDA（Harvoni®、Epclusa® and Vosevi®）Played a key role in the research and development process, andExtending to the research and development of hepatitis B curative drugs. In addition,Dr. Guo Cheng also led the completion of several important projects, such ascccDNA inhibitors, HBsAg inhibitors, Precision Bioscience gene editing, and CAR-T related gene editing projects.

Yang Chengyong, as the co-founder and Chief Strategy Officer, is the formerGileadDirector of Drug Metabolism and Pharmacokinetics. During his 14 years at Gilead, Dr. YangCo-led the development of the above three transformative hepatitis C treatment drugs and played a key role in the clinical research, development, and regulatory approval of Epclusa®. In view of Dr. YangFor his significant contributions to the development of hepatitis C drugs, he received the American Chemical Society Award in 2015.（ACS）"The Chemistry Hero Award"

TianMr. Xue Tao Wen serves as the Chief Commercial Officer of AusperBio.With over 20 years of profound experience in the medical industry, he has successively held key positions such as Regional Manager, Senior Sales Director, and Vice President at Pfizer, Bayer, Gilead, and other companies.

Currently, the most core aspect of AusperBio isMed-Oligo™ Technology Platform, this technologyThe initial application focused on the hepatitis B virus. (HBV) Treatment has now expanded to a wide range of severe chronic diseases in humans.

AHB-137 is a non-conjugated antisense oligonucleotide developed based on this platform.（ASO）, with the potential to becomeCornerstone Therapy for Clinical Cure of Chronic Hepatitis Bpotential. Currently, the drug is undergoing Phase III clinical trials in mainland China, Phase II clinical trials for combination therapy and treatment-naive patients, while simultaneously advancing overseas Phase II clinical trials.

AHB-137 has been studied in preclinical research and presented at multiple international authoritative academic conferences.(Including 2023–2025 EASL, 2024 AASLD, and 2025 APASL)Demonstrated excellent data and gained widespread attention.

At the 2025 EASL Conference, AusperBio disclosed the product for the first time.IIPhase b Clinical Interim Data.

Data shows,

• In the 24-week treatment group, 75% of the subjects reached this primary endpoint; in the 16-week treatment group, 66% of the subjects reached this primary endpoint.

• Among the subjects who reached the primary endpoint,More than 80% of subjects achieved HBsAg clearance within 12 weeks of treatment., and at the end of treatment, 54% and 33% of subjects in the 24-week and 16-week groups, respectively, achieved seroconversion of hepatitis B surface antibodies.

• AHB-137 demonstrated good tolerability and effective safety in both treatment groups.

BesidesAHB-137: AusperBio Has Two Other Therapeutic Hepatitis B VaccinesAHB-201 andAHB-837 is in the preclinical stage.

Another Technical PlatformMed-Oligo™ is mainly used for the development of oligonucleotide conjugate drugs.Drug delivery is an important challenge for oligonucleotide therapies. Med-Oligo™ ASO molecules can be conjugated with various ligands to achieve targeted delivery to different tissues and organs. Currently, AusperBio is advancing multiple oligonucleotide conjugate drug pipelines based on this platform for the treatment of other chronic diseases.

In addition to a luxurious executive team and excellent clinical data, the reason why these capital giants are willing to continue supporting AusperBio is undoubtedly due to the enormous clinical demand and market potential behind it.

Chronic hepatitis B is one of the major public health issues globally.According to the World Health Organization, there were approximately 316 million people with chronic hepatitis B infection globally in 2019.China is one of the countries with a severe global burden of hepatitis B, with approximately 75 million people currently living with chronic hepatitis B virus infection.

A large patient population brings significant market potential.。According to the report estimation,As the diagnosis and treatment rate of hepatitis B gradually increases, and more innovative hepatitis B drugs come to market, the scale of China's hepatitis B drug market is expected to experience significant growth, potentially exceeding 75 billion yuan by 2030.

In the Phase IIb study, 75% of subjects treated with AHB-137 achieved HBsAg clearance and HBV DNA undetectability during the 24-week treatment period.With this encouraging clinical data, it has tremendous potential to make a significant impact on this blockbuster market. Driven by both capital and innovation, AusperBio is steadily advancing toward the first tier in the global race to cure hepatitis B.

In addition, AusperBio's Med-Oligo™ technology platform not only supports the development of AHB-137 but also offers platform scalability, extending to other liver-related diseases and extrahepatic targets, providing continuous momentum for the company's long-term growth.